drugset / Trial / NCT07116967
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RandomizedParallel-groupOpen-labelTreatment
Summary
A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis
Timeline
- Start
- 2025-09-22
- Primary completion
- 2031-01-16
- Completion
- 2031-01-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CRAVACITINIB | Small molecule | — | — |
| Comparator | Ustekinumab | Monoclonal antibody | — | — |